Studying how weight-loss medications affect energy use and body composition in obesity
Observes how semaglutide and tirzepatide affect energy use and body makeup in adults with obesity.
Key facts
- Who runs it
- University of Pisa
- Where
- Pisa, ItalySee the site
- Trial code
- Registry title
- 24-h Energy Expenditure and Anti-obesity Medication
- Status
- Enrolling by invitation
- People taking part
- 30 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 1 Dec 2026
- Type of study
- Observational
- Treatments tested
- anti obesity medication
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity to study how semaglutide and tirzepatide change energy use and body composition.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- BMI of 30 kg/m² or more, or BMI of 27 kg/m² or more with at least one weight-related health problem
Main reasons for not taking part
- Diabetes
- Pregnancy or breastfeeding
- History of medullary thyroid cancer
- Psychiatric conditions that make it hard to follow the study
- Cardiovascular events or end-organ damage
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Body mass index (BMI) >= 30 kg/m² or >= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months)
- informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage
Who cannot take part
- psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation
- diabetes
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in Italy
- University Hospital of PisaPisa, ItalyNo longer taking part
About the trial
What the trial wants to find out
This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
The group in the trial
- antiobesity medication and energy expenditure
patients with obesity for the administration anti-obesity medication (Semaglutide or Tirzepatide) for the clinical use.
Treatment: anti obesity medication
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effects of Anti-obesity Medications on 24h Energy Metabolism and Body Composition in Patients With Obesity
- Plain-language title
- Studying how weight-loss medications affect energy use and body composition in obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07041983, who can take part
- Record updated
- 5 May 2026